FDA gives OK to Mesoblast for mesenchymal precursor cell production

11/20/2012 | Australian Life Scientist

Mesoblast and the FDA have reached an agreement regarding the production process for mesenchymal precursor cells to be used in late-stage clinical trials for the treatment of congestive heart failure and other conditions. The FDA and Mesoblast put in place a path for the possible commercial production of the company's cell therapy products.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC
Senior Counsel Commercial
RAI Services Company
Winston Salem, NC
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL